Laval – October 12, 2026 -- A six-month pilot of a standardized cirrhosis clinical pathway raised follow-up office visit adherence by 9.0% in relative terms, to 51.1% from 46.9%, across 4,251 patients in five community gastroenterology practices, Bausch Health Companies Inc. and its GI unit Salix Pharmaceuticals announced.

San Carlos, Calif. – October 12, 2026 -- Noah Medical's Galaxy robotic bronchoscopy platform delivered a 96.7% strict diagnostic yield in a 31-patient multi-center study, and an 89% yield with a cost-benefit ratio above 1 in a separate community hospital series, according to two data sets presented at the CHEST 2025 Annual Meeting in Chicago.

Jersey City – October 11, 2026 -- Subcutaneous (SC) infliximab delivered clinical remission in 71.4% of matched patients with ileum-dominant Crohn's disease at Week 54, against 51.4% for intravenous (IV) infliximab, according to a late-breaking analysis Celltrion USA will present for ZYMFENTRA (infliximab-dyyb) at the American College of Gastroenterology (ACG) 2026 Annual Scientific Meeting in Nashville, Tennessee.

Plainsboro, N.J. – – September 29, 2026 -- Novo Nordisk reported that adults with type 2 diabetes who escalated their semaglutide dose to 2 mg showed a statistically significant 6% lower risk of major adverse cardiovascular events (MACE) compared with patients who switched to tirzepatide, according to real-world data presented at the European Association for the Study of Diabetes (EASD) Annual Meeting 2026 in Milan.